Investor Relations

Copyright West LLC. Minimum 15 minutes delayed.

 

 

Copyright West LLC. Minimum 15 minutes delayed.

 

 

Press Releases
10-Mar-20

Innate Pharma Reports Full Year 2019 Financial Results and Business Update

Innate globally expands its capital markets presence with a successful NASDAQ IPO and Global Offering that provided gross proceeds of $79.1 million (€71.5 million 1 ) Monalizumab to advance to a Phase III clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients

10-Mar-20

First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors

Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic MARSEILLE, France , March 10, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA)

13-Jan-20

French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new